| Literature DB >> 28629136 |
Nour Zahi Gammoh1, Lothar Rink2.
Abstract
Micronutrient homeostasis is a key factor in maintaining a healthy immune system. Zinc is an essential micronutrient that is involved in the regulation of the innate and adaptive immune responses. The main cause of zinc deficiency is malnutrition. Zinc deficiency leads to cell-mediated immune dysfunctions among other manifestations. Consequently, such dysfunctions lead to a worse outcome in the response towards bacterial infection and sepsis. For instance, zinc is an essential component of the pathogen-eliminating signal transduction pathways leading to neutrophil extracellular traps (NET) formation, as well as inducing cell-mediated immunity over humoral immunity by regulating specific factors of differentiation. Additionally, zinc deficiency plays a role in inflammation, mainly elevating inflammatory response as well as damage to host tissue. Zinc is involved in the modulation of the proinflammatory response by targeting Nuclear Factor Kappa B (NF-κB), a transcription factor that is the master regulator of proinflammatory responses. It is also involved in controlling oxidative stress and regulating inflammatory cytokines. Zinc plays an intricate function during an immune response and its homeostasis is critical for sustaining proper immune function. This review will summarize the latest findings concerning the role of this micronutrient during the course of infections and inflammatory response and how the immune system modulates zinc depending on different stimuli.Entities:
Keywords: homeostasis; infection; inflammation; zinc
Mesh:
Substances:
Year: 2017 PMID: 28629136 PMCID: PMC5490603 DOI: 10.3390/nu9060624
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Activation of Toll-like receptor (TLR) signaling pathways is mediated by a complex array of proteins. When TLRs bind ligands, dimerization of the ectodomain of TLRs is induced, bringing their cytoplasmic Toll/IL-1R domains together, resulting in the recruitment of intracellular adapter proteins and initiation of downstream signaling events. Following this, the Toll–IL-1-resistence (TIR) domains of TLRs engage TIR domain-containing adaptor proteins (either myeloid differentiation primary-response protein 88 (MYD88) or TIR domain-containing adaptor protein inducing IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM)). This in turn stimulates downstream signaling pathways that involve interactions between IL-1R-associated kinases (IRAKs) and the adaptor molecules TNF receptor-associated factors (TRAFs), and that lead to the activation of the mitogen-activated protein kinases (MAPKs) JUN N-terminal kinase (JNK) and p38, and to the activation of transcription factors. Two groups of transcription factors are activated downstream of TLR signaling; nuclear factor-κB (NF-κB) and interferon-regulatory factors (IRFs). This TLR signaling pathway leads to the induction of proinflammatory cytokines. Zinc influences this pathway on multiple levels. It augments MyD88-dependent signaling whereas inhibiting TRIF-mediated activation of IRF3/7. It has been shown that zinc inhibits IRAK thereby inhibiting further signal transductions. In vitro, zinc also directly impaired LPS-induced IKK activity [45].
Figure 2Pro-inflammatory signaling pathway influences by zinc. Similar to TLR signaling, IL-1, and TNF-R signaling pathways converge on a common IκB kinase complex that phosphorylates the NF-κB inhibitory protein, resulting in the release of NF-κB and its translocation to the nucleus. Zinc prevents the dissociation of NF-κB from its corresponding inhibitory protein, thus preventing the nuclear translocation of NF-κB and inhibiting subsequent inflammation. Zinc also inhibits IL-6-mediated activation of STAT3. Zinc acts as anti-inflammatory element influencing major pro-inflammatory signaling pathways.
Figure 3Anti-inflammatory signaling pathways influenced by free zinc. (a) TGFβ signaling is dependent on a dynamic on and off switch in Smad activity. Free zinc is a cofactor in Smad proteins and promote Smad 2/3 nuclear translocation and transcriptional activity. (b) zinc regulates IL-2 signaling pathway via blocking MAP kinase phosphatase (MKP) in extracellular signal-regulated kinases (ERK) 1/2 pathways and Phosphatase and tensin homologue (PTEN) which opposes phosphoinositide 3-kinase (PI3K) function in PI3k/Akt pathway. (c) free zinc phosphorylates STAT6 and promotes translocation of STAT dimers into the nucleus, hence promote the anti-inflammatory effects of Il-4.
Zinc supplementation and viral diseases (updated from [106]).
| Disease | Zinc Species | Zinc Dosage | Period | Participation | Effect of Zinc Supplementation | Reference |
|---|---|---|---|---|---|---|
| more than 12 different studies, analyzing the therapeutic effects of zinc | variable results, reduced duration of symptoms if administered within 24 h of onset | [ | ||||
| zinc sulfate | 15 mg daily | 7 months | 100 (Z), | lower mean number of colds demonstrating the prophylactic effect of zinc | [ | |
| Not specified | 12 mg for women and 15 mg for men/day | 18 months | 115 (Z) | no effect on viral load. four-fold reduction in the likelihood of immunological failure. Reduced the rate of diarrhea by more than half. No significant difference in mortality | [ | |
| Chelated zinc | 15 mg daily | 12 months | Low: 5 (Z)/7 (P) | CD4+ cell count significantly increased | [ | |
| Zinc sulfate | 20 mg daily | 24 weeks | 26 (Z) | no effect on the increase in CD4%, decrease in viral load, anthropometric indices, and morbidity profile in HIV-infected children started on ART | [ | |
| Zinc sulfate | 45.5 mg daily | 1 month | 29 (Z) | increase or stabilization in body weight; increase in plasma zinc levels, CD4+ T cells and plasma active zinc-bound thymulin; reduced or delayed frequency of opportunistic infections due to | [ | |
| Zinc gluconate | 45 mg three time daily | 15 days | 5 (Z) | increased zinc concentrations in red blood, HLA-DR + cells, stimulation of lymphocyte transformation and phagocytosis of opsonized zymosan by neutrophils | [ | |
| Zinc sulfate | 10 mg daily | 6 months | 44 (Z) | no effect on HIV viral load; decreased morbidity from diarrhea | [ | |
| Zinc sulfate | 50 mg daily | 1 month | 31 (Z) | no improvements in immune responses to tuberculosis, CD4/CD8 ratio, lymphocyte subsets, and viral load | [ | |
| Zinc sulfate | 25 mg daily | 6 months | 200 (Z) | when supplemented to pregnant HIV-positive women, no effect on birth outcomes or T-lymphocyte counts, and negative effects on hematological indicators | [ | |
| Zinc sulfate | 25 mg daily | 6 months | 200 (Z) | increased risk of wasting | [ | |
| 50 (Z) | no effect on viral load | |||||
| Zinc gluconate | 50 mg daily | 6 days | 44 (Z) | no improvements in antibody responses to a pneumococcal conjugate vaccine | [ | |
| Not specified | 10 mg | 60 days | 26 (Z + 6400 mg/day Branched-chain amino acids) | BCAA-to-tyrosine ratio (BTR) and zinc levels were significantly increased compared with the placebo group. supplementation reduced the serum α-fetoprotein AFP levels in patients who had elevated serum AFP levels at baseline | [ | |
| Polapre-zinc | 150 mg | 48 weeks | 11 (Z) | serum alanine aminotransferase (ALT) level is lower in zinc group compared to control group. HCV RNA disappeared in all patients in the zinc group and in 80% control patients at 48 week. Polaprezinc supplementation decreased plasma thiobarbituric acid reactive substances and prevented the decrease of polyunsaturated fatty acids of erythrocyte membrane phospholipids | [ | |
| Polapre-zinc | 17 mg twice a day | 24 weeks | 40 (Z) | zinc supplementation increases serum zinc levels and improves the response to IFN-α therapy | [ | |
| Zinc gluconate | 50 mg daily | 6 months | 18 (Z) | increased serum zinc levels; decreased incidences of gastrointestinal disturbances, body weight loss, and mild anemia | [ | |
Z—zinc, P—placebo, C—control.
Zinc supplementation and bacterial infectious diseases (updated from [106]).
| Disease | Zinc Species | Zinc Dosage | Period | Participation | Effect of Zinc Supplementation | Reference |
|---|---|---|---|---|---|---|
| multiple different studies | decreased duration, severity and occurrence of diarrhea | [ | ||||
| Not specified | 20 mg daily | 14 days | 41 (Z) | supplementation with a combination of micronutrients and vitamins was not superior to zinc alone, confirming clinical benefit of zinc in children with diarrhea | [ | |
| Zinc sulfate | 20 mg daily | 5 months | 134 (Z) | reduced acute lower respiratory tract infection morbidity | [ | |
| zinc gluconate | 10 mg daily | 60 days | 48 (Z) | reduced episodes of acute lower respiratory infections and severe acute lower respiratory infections. Increased infection free days | [ | |
| Zinc oxide | 5 mg daily | 12 months | 162 (Z) | decreased incidence of upper respiratory tract infections and diarrhoeal disease episodes | [ | |
| zinc gluconate | 10 mg daily | 6 months | 298 (Z) | increased plasma zinc levels; decreased episodes of infection | [ | |
| Zinc acetate | 10 mg twice a day | 5 days | 76 (Z) | increased serum zinc levels and recovery rates from illness and fever in boys | [ | |
| Zinc sulfate | 15 mg daily | 6 months | 40 (Z) | increased plasma retinol concentrations; earlier sputum conversion and resolution of X-ray lesion area | [ | |
| zinc sulfate | 220 mg daily | 18 months | 8 (Z) | reduced dose of clofazimine; withdrawal of steroids; toleration of dapsone; reduced incidence and severity of erythema nodosum leprosum; gradual decrease in the size of granuloma; gradual increase in the number of lymphocytes | [ | |
| zinc sulfate | 220 mg daily | 18 months | 15 (Z) | decreased erythema, edema, and infiltration; regrowth of eyebrows; reduced bacterial index of granuloma; increased serum zinc levels, neovascularization, and endothelial cell proliferation | [ | |
| Zinc acetate | 200 mg twice a day | 13 weeks | 17 (Z) | increased serum zinc levels and delayed hypersensitivity reactions; decreased size of skin nodules; disappearance of erythema; regrowth of eyebrows | [ | |
| zinc sulfate | 220 mg daily | 4 months | 40 (Z) | improvements on frequency, duration, and severity of erytheme nodosum leprosum reactions; reduction in steroid requirement | [ | |
| zinc acetate | 1.3 mg/kg three times a day | 1 month | 16 (Z) | increased intestinal mucosal permeability and better nitrogen absorption; increased serum zinc and alkaline phosphatase activity | [ | |
| zinc acetate | 20 mg daily | 2 weeks | 28 (Z) | increased serum zinc levels, lymphocyte proliferation in response to phytohemagglutinin and plasma invasion plasmid-encoded antigen-specific IgG titers | [ | |
| zinc acetate | 20 mg daily | 2 weeks | 28 (Z) | increased serum zinc levels, serum shigellacidal antibody titers, CD20+ cells, and CD20+CD38+ cells | [ | |
| Not specified | 20 mg daily | 2 weeks | 14 (Z) | faster recovery from acute illness. Increased mean body weight. Fewer episodes of diarrhoea | [ | |
| polapre zinc | 150 mg twice a day | 7 days | 33 (Z) | administration of zinc together with antimicrobial therapy increased cure rate of | [ | |
Z–zinc, P–placebo, C–control; Diarrhea and respiratory infections can be caused by nonbacterial pathogens. The mentioned studies do not specific the causative agent; * micronutrient combination: zinc, 20 mg; iron, 10 mg; copper, 2 mg; selenium, 40 mg; vitamin B12, 1.4 mg; folate, 100 mg.
Zinc supplementation and parasites (updated from [103]).
| Disease | Zinc Species | Zinc Dosage | Period | Participation | Effect of Zinc Supplementation | Reference |
|---|---|---|---|---|---|---|
| Not specified | 10 mg 6 times/week | 6 months | 74 (Z + 1 single dose of 200 000 IU Vit A) | significant decrease in the prevalence malaria. Lower malaria episodes. Time to first malaria episode was longer. 22% fewer fever episodes than the placebo group | [ | |
| Zinc gluconate | 10 mg 6 times/week | 46 weeks | 136 (Z) | reduction in
| [ | |
| Zinc acetate/zinc gluconate | 70 mg twice a week | 15 months | 55 (Z) | not statistically significant trend towards fewer malaria episodes; no effect on plasma and hair zinc, diarrhea, and respiratory illness | [ | |
| Zinc sulfate | 12.5 mg 6 times/week | 6 months | 336 (Z) | increased serum zinc levels; reduced prevalence of diarrhea | [ | |
| Zinc sulfate | 20 or 40 mg daily | 4 days | 473 (Z) | increased plasma zinc, no effect on fever, parasitemia, or hemoglobin concentration | [ | |
| Zinc sulfate | 20 mg daily | 7 months | 191 (Z) | no significant effect on P. vivax incidence; significantly reduced diarrhea morbidity | [ |
Z–zinc, P–placebo.